MedTrace Logo

A Single and Multiple Ascending Doses, Relative Bioavailability, Food Effect, and Drug-Drug Interaction Study of NX-5948 in Healthy Volunteers

NCT06717269 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 223

Last updated 2026-07-28

No results posted yet for this study

Summary

This is a multiple part, multiple cohort study evaluating single and multiple ascending doses, relative bioavailability, food effect, and drug-drug interaction of NX-5948 in healthy volunteers.

Conditions

  • Healthy Volunteer

Interventions

DRUG

NX-5948

Administered orally in tablet or capsule form

DRUG

Esomeprazole

Administered orally in capsule form

DRUG

Placebo

Administered orally matching NX-5948 tablets

DRUG

Famotidine

Administered orally in tablet form

DRUG

Midazolam

Administered orally in syrup form

DRUG

Digoxin

Administered orally in tablet form

DRUG

Rosuvastatin

Administered orally in tablet form

DRUG

Quinidine

Administered orally in tablet form

DRUG

NX-5948

Administered in capsule form

Sponsors & Collaborators

  • Nurix Therapeutics, Inc.

    lead INDUSTRY

Principal Investigators

  • Study Director · Nurix Therapeutics

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
19 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-11-30
Primary Completion
2026-05-01
Completion
2026-05-01
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06717269 on ClinicalTrials.gov